FzioMed

Name

FzioMed

Legal name

Fziomed, Inc.

Website

https://fziomed.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Surgical Adhesion Barrier Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

akta.pro secondary industry

Adhesives & Sealants Chemicals (IMAEABAA)

Keywords

• Surgical adhesion barriers
• Postsurgical adhesion prevention
• Absorbable polymer gels
• Medical device manufacturing
• Biomaterials technology

Headquarters

HQ city

San Luis Obispo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Medical Device Sales: Fziomed generates revenue through the sale of its proprietary adhesion barrier gel products (Oxiplex, Dynavisc, Intercoat IU, Intercoat AP) to healthcare providers, hospitals, and surgeons performing various surgical procedures. Products are sold through a distributor network and directly in the US market.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

FzioMed develops, manufactures, and commercializes a family of synthetic absorbable adhesion barrier gels based on a proprietary dual-polymer platform combining carboxymethylcellulose (CMC) and polyethylene oxide (PEO). The portfolio includes Oxiplex Absorbable Gel for lumbar spine surgery, Dynavisc for tendon and peripheral nerve procedures, Intercoat IU for intrauterine surgery, and Intercoat AP for abdominal and pelvic surgery, sold to hospitals, surgical centers, and surgeons. Products act as temporary protective physical barriers at the surgical site for up to 30 days to reduce postoperative adhesion formation.

Product overview

FzioMed is a medical device company specializing in postsurgical adhesion prevention products based on a proprietary dual-polymer technology platform combining carboxymethylcellulose (CMC) and polyethylene oxide (PEO). The company offers four distinct adhesion barrier gel products tailored for specific surgical applications: Oxiplex Absorbable Gel for spine surgery (available in the US), Dynavisc for tendon and peripheral nerve procedures, Intercoat IU/Oxiplex-IU for intrauterine surgery, and Intercoat AP/Oxiplex-AP for abdominal and pelvic surgery. All products are synthetic, absorbable gels that create a temporary physical barrier to reduce postoperative adhesion formation, with over 1 million patients treated worldwide since 2002.

Differentiator

Problem solved

Functional benefit

Brands

• Oxiplex: FDA-authorized absorbable gel for reducing postoperative leg pain and neurological symptoms in lumbar spine surgery.
• Dynavisc
• Intercoat IU (Oxiplex/IU)
• Intercoat AP (Oxiplex/AP)

Products and services

• Oxiplex Absorbable Gel FDA De Novo authorized synthetic absorbable dual-polymer gel (carboxymethylcellulose and polyethylene oxide) used as an adjunct to lumbar spinal surgery (discectomy, laminectomy, laminotomy) in adult patients with leg pain, back pain, and neurological symptoms. It acts as a temporary protective barrier coating sensory nerves from surrounding tissues and inflammatory mediators. Supplied sterile in a 3 mL syringe with flexible applicator.
• Dynavisc Adhesion Barrier Gel Synthetic absorbable dual-polymer gel adhesion barrier formulated for tendon and peripheral nerve procedures, including flexor tendon repair, tenolysis, Dupuytren's contracture, neurolysis, and carpal tunnel syndrome. Provides temporary protective separation of tissues adjacent to surgical sites during healing to reduce adhesion formation. Supplied sterile in a 1 mL syringe with flexible applicator.
• Intercoat IU Adhesion Barrier Gel (Oxiplex/IU) Synthetic absorbable dual-polymer gel adhesion barrier (also sold as Oxiplex/IU) intended as an adjunct to intrauterine procedures such as dilation and curettage, myomectomy, adhesiolysis, and hysteroscopic surgeries to reduce the incidence, extent, and severity of adhesions. Supplied sterile in a 10 mL syringe with applicator designed specifically for intrauterine use.
• Intercoat AP Adhesion Barrier Gel (Oxiplex/AP) Synthetic absorbable dual-polymer gel adhesion barrier (also sold as Oxiplex/AP) intended as an adjunct to abdominal and pelvic surgery (hernia repair, bariatric procedures, hysterectomy, endometriosis surgery, tubal and ovarian surgeries) for reducing postoperative adhesions. Supplied sterile with two 20 mL syringes and a laparoscopic applicator designed for single, consistent layer application.

Quantifiable outcome

• Higher rates of substantial and complete leg pain relief in 134-patient randomized double-blind multicenter study compared with surgery alone
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Regional players

• Seikagaku Corporation: Seikagaku is a Japanese specialty pharmaceutical and medical device company producing hyaluronic acid-based surgical and intra-articular products, including adhesion-related therapies. It is comparable to FzioMed as a specialty adhesion prevention player, though primarily serving the Japanese and Asian markets.
• Anges MG: Anges is a Japanese biotech and medical device company with surgical and wound-healing adjacencies, including products relevant to adhesion prevention. It is comparable as a regional specialty surgical products player in the same therapeutic category as FzioMed, primarily operating in Asia.

Broad incumbents

• Ethicon (Johnson & Johnson MedTech): Ethicon markets INTERCEED absorbable adhesion barrier for gynecologic and abdominal surgery, a direct competitor to FzioMed's Intercoat IU and Intercoat AP. Ethicon's scale, surgeon relationships, and surgical portfolio make it the dominant incumbent competing against FzioMed in adhesion prevention.
• Baxter International: Baxter produces Adept, an adhesion reduction solution used in abdominal/pelvic surgery, directly overlapping with FzioMed's Intercoat AP. As a large diversified medical products company, Baxter competes with FzioMed in the surgical adhesion barrier category while serving a much broader hospital customer base.
• Medtronic: Medtronic is a leading spine surgery device company with deep relationships with US spine surgeons and hospitals performing the lumbar discectomy and laminectomy procedures targeted by FzioMed's Oxiplex gel, making it both a channel influencer and adjacent competitor.

Direct peers

• MAST Biosurgery: MAST Biosurgery is a specialty surgical company developing anti-adhesion and surgical consumable products, directly comparable to FzioMed's adhesion prevention portfolio. The company competes with FzioMed in gynecologic, spine, and general surgical adhesion prevention markets.
• Anika Therapeutics: Anika Therapeutics develops hyaluronic acid-based viscosupplementation and surgical products, including adhesion barrier-adjacent therapies used in orthopedic and surgical applications. Its HA-based technology platform represents a direct mechanistic alternative to FzioMed's CMC/PEO gel approach.
• Innocoll Holdings: Innocoll develops collagen-based surgical and adhesion prevention products, including biodegradable implantable matrices. Its specialty surgical barrier portfolio competes with FzioMed's gel-based adhesion prevention products in gynecologic and general surgery applications.
• Integra LifeSciences: Integra LifeSciences develops and markets regenerative and surgical device technologies including dural repair and adhesion-related products used in spine and neurosurgery, directly comparable to FzioMed's Oxiplex gel in surgical applications and specialty channels.

Emerging players

• Pacira BioSciences: Pacira BioSciences develops specialty injectable and postsurgical pain/therapeutic products for the surgical market. While focused on non-opioid pain rather than adhesion barriers, its commercial model targeting hospital-based surgeons and surgical specialists is comparable to FzioMed's go-to-market approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fziomed-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FzioMed